Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects.

Morice A, Unwin RJ, Sever PS

Lancet (London, England)1 Nov 1983Cited by 71 (Europe PMC)

PMID6139572DOI10.1016/s0140-6736(83)91272-2PepBankPUB-06139572

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In asthmatic volunteers, intravenous VIP caused significant bronchodilatation.
In plain wordsIn people with asthma, VIP given into a vein opened the airways.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseBronchodilatation
Study
n = 7
Outcome group
Respiratory function · Respiratory
Studied dose
6 pmol/kg/min · intravenous · 15 minAs given in this study (human).
Source sentences
Summary
Vasoactive intestinal peptide (VIP) caused significant bronchodilatation in seven asthmatic volunteers when given intravenously at the rate of 6 pmol/kg/min for 15 min during a double-blind study.
Report a problemFND-0613957201
02HumanRandomized controlled trialSafety outcome
In asthmatic volunteers, tachycardia was observed during VIP infusion.
In plain wordsIn people with asthma, VIP infusion made the heart beat faster.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseTachycardia
Study
n = 7
Outcome group
Adverse events · Cardiovascular
Studied dose
6 pmol/kg/min · intravenous · 15 minAs given in this study (human).
Source sentences
Summary
Tachycardia
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (VIP) caused significant bronchodilatation in seven asthmatic volunteers when given intravenously at the rate of 6 pmol/kg/min for 15 min during a double-blind study
Report a problemFND-0613957202
03HumanRandomized controlled trialSafety outcome
In asthmatic volunteers, cutaneous flushing was observed during VIP infusion.
In plain wordsIn people with asthma, VIP infusion made the skin flush.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseCutaneous flushing
Study
n = 7
Outcome group
Adverse events · Whole body
Studied dose
6 pmol/kg/min · intravenous · 15 minAs given in this study (human).
Source sentences
Summary
Tachycardia and cutaneous flushing were observed during the infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (VIP) caused significant bronchodilatation in seven asthmatic volunteers when given intravenously at the rate of 6 pmol/kg/min for 15 min during a double-blind study
Report a problemFND-0613957203
04HumanRandomized controlled trialEfficacy outcome
In asthmatic volunteers, VIP infusion ameliorated histamine-induced bronchoconstriction in all subjects.
In plain wordsIn people with asthma, VIP infusion reduced airway narrowing caused by histamine in all subjects.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseHistamine-induced bronchoconstriction
Study
n = 7
Outcome group
Respiratory function · Respiratory
Studied dose
6 pmol/kg/min · intravenous · 15 minAs given in this study (human).
Source sentences
Summary
VIP also ameliorated histamine-induced bronchoconstriction in all subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (VIP) caused significant bronchodilatation in seven asthmatic volunteers when given intravenously at the rate of 6 pmol/kg/min for 15 min during a double-blind study
Report a problemFND-0613957204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.